{"filing":{"accession_number":"0001213900-26-073158","cik":"0001023549","ticker":"XTLB","company_name":"XTL BIOPHARMACEUTICALS LTD","form":"6-K","filing_date":"2026-06-29","report_date":null,"primary_document":"ea0296376-6k_xtlbio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1023549/000121390026073158/ea0296376-6k_xtlbio.htm"},"events":[{"id":14698,"run_id":13092,"accession_number":"0001213900-26-073158","anchor_item_number":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The 6-K discloses results of an Extraordinary General Meeting of Shareholders held on June 29, 2026, where shareholders approved four material resolutions: (1) acquisition of 80–100% of Psyga Bio Ltd. via private placement of shares and warrants; (2) private placement of up to $1.5M from specified investors; (3) increase of authorized share capital by 2.9B shares; and (4) appointment of auditors. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, and the underlying transactions (M\u0026A, dilutive issuance, auditor appointment) are material to investors.","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-06-29","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":12205,"accession_number":"0001213900-26-073158","item_number":null,"item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The 6-K discloses results of an Extraordinary General Meeting of Shareholders held on June 29, 2026, where shareholders approved four material resolutions: (1) acquisition of 80–100% of Psyga Bio Ltd. via private placement of shares and warrants; (2) private placement of up to $1.5M from specified investors; (3) increase of authorized share capital by 2.9B shares; and (4) appointment of auditors. This is a classic shareholder vote results disclosure under Item 5.07 equivalent, and the underlying transactions (M\u0026A, dilutive issuance, auditor appointment) are material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-29T20:40:40.036889+00:00","company_name":"XTL BIOPHARMACEUTICALS LTD","ticker":"XTLB","filing_date":"2026-06-29"}]}